Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rakhee Vaidya

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Mayo Clinic Proceedings|December 4, 2009
Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent yearsRakhee Vaidya, Sergio Siragusa, Jocelin Huang, et al.
Leukemia & Lymphoma|December 19, 2017
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective studyZanetta S Lamar, Andrew Dothard, LeAnne Kennedy, et al.
Leukemia & Lymphoma|September 6, 2023
Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoidesJoseph Pena, Deborah Cull, Lindsay C Strowd, et al.
Blood|April 1, 2011
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survivalRakhee Vaidya, Domenica Caramazza, Kebede H Begna, et al.
Blood|September 2, 2011
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patientsAyalew Tefferi, Thitina Jimma, Naseema Gangat, et al.
Leukemia & Lymphoma|September 16, 2020
Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantationTimothy J Voorhees, Kavya K Kannan, Jonathan Galeotti, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 5, 2016
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin LymphomaZanetta S Lamar, Nora Fino, Jodi Palmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2025
Cognitive Performance in Patients With Multiple Myeloma Treated With an Autologous Stem Cell Transplant: Results of the Brilliant StudyCesar Rodriguez, Melanie Tam, David Hurd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusNaseema Gangat, Domenica Caramazza, Rakhee Vaidya, et al.
Mayo Clinic Proceedings|January 4, 2012
One thousand patients with primary myelofibrosis: the mayo clinic experienceAyalew Tefferi, Terra L Lasho, Thitina Jimma, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Mayo Clinic Proceedings|December 4, 2009
Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent yearsRakhee Vaidya, Sergio Siragusa, Jocelin Huang, et al.
Leukemia & Lymphoma|December 19, 2017
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective studyZanetta S Lamar, Andrew Dothard, LeAnne Kennedy, et al.
Leukemia & Lymphoma|September 6, 2023
Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoidesJoseph Pena, Deborah Cull, Lindsay C Strowd, et al.
Blood|April 1, 2011
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survivalRakhee Vaidya, Domenica Caramazza, Kebede H Begna, et al.
Blood|September 2, 2011
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patientsAyalew Tefferi, Thitina Jimma, Naseema Gangat, et al.
Leukemia & Lymphoma|September 16, 2020
Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantationTimothy J Voorhees, Kavya K Kannan, Jonathan Galeotti, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 5, 2016
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin LymphomaZanetta S Lamar, Nora Fino, Jodi Palmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2025
Cognitive Performance in Patients With Multiple Myeloma Treated With an Autologous Stem Cell Transplant: Results of the Brilliant StudyCesar Rodriguez, Melanie Tam, David Hurd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusNaseema Gangat, Domenica Caramazza, Rakhee Vaidya, et al.
Mayo Clinic Proceedings|January 4, 2012
One thousand patients with primary myelofibrosis: the mayo clinic experienceAyalew Tefferi, Terra L Lasho, Thitina Jimma, et al.
Pageof 3